FIGURE 3.

LRG1 expression is associated with melanoma progression and recurrence. A–D, Normalized protein expression (log₂) values of LRG1, measured by MS for matched stage III and IV patients (n = 64; A), non-responsive patients at baseline of the OpACIN-neo study (n = 20; B), and at week 6 after neoadjuvant ICB treatment of the OpACIN-neo study (n = 20; C) and all patients at baseline of the OpACIN-neo study (n = 82; D). A two-tailed paired Student t test was used to determine statistical significance between stage III and stage IV samples. A two-tailed unpaired Student t test was used to compare patients with and without a recurrence or response of the OpACIN-neo study. E, sROC curves to define the optimal cutoff (marked by the blue dot) for all patients (left) and nonresponding patients (right) of the OpACIN-neo study for baseline LRG1 expression. The AUC for all patients was 0.598 and for nonresponder patients 0.780, with an optimal cutoff of 24.5504. A Kaplan–Meier curve showing EFS for all patients (F) and nonresponder patients (G) of the OpACIN-neo study with either a high (red) or low (blue) expression of LRG1. The asterisk denotes a patient (in LRG1 low group) who died because of irAEs. H, A Kaplan–Meier curve showing overall survival for nonresponder patients of the OpACIN-neo study with either a high (red) or low (blue) expression of LRG1. P value was calculated using the log-rank test (two-sided) and significance is indicated. *, P < 0.05; ***, P <0.001.